← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $623B	3,682	-73	-2%	$260B
2	2 Merck MRK $372B	3,215	-42	-1%	$199B
3	3 AbbVie ABBV $510B	3,112	+33	+1%	$183B
4	4 Pfizer PFE $169B	2,928	-116	-4%	$131B
5	5 Amgen AMGN $238B	2,502	+111	+5%	$109B
6	6 Bristol-Myers Squibb BMY $125B	2,389	-93	-4%	$91.2B
7	7 Gilead Sciences GILD $197B	1,683	-19	-1%	$78.1B
8	8 Novartis NVS $287B	1,222	+21	+2%	$15.1B
9	9 Regeneron Pharmaceuticals REGN $83B	1,177	+13	+1%	$75.1B
10	10 AstraZeneca AZN $261B	1,074	-17	-2%	$33.8B
11	11 GSK GSK $99.3B	846	+19	+2%	$10.4B
12	12 DELISTED Exact Sciences EXAS	624	-28	-4%	$11.2B
13	SGEN 13 DELISTED Seagen Inc. Common Stock SGEN	616	+22	+4%	$36.3B
14	14 Incyte INCY $23.1B	529	+2	+0.4%	$12.4B
15	15 Jazz Pharmaceuticals JAZZ $14.1B	484	+13	+3%	$7.33B
16	16 Lantheus LNTH $6.53B	400	-31	-7%	$4.9B
17	17 Exelixis EXEL $15.3B	399	+20	+5%	$5.78B
18	18 Halozyme HALO $13.8B	389	+19	+5%	$4.71B
19	19 Natera NTRA $57.8B	319	+2	+0.6%	$5.09B
20	20 Takeda Pharmaceutical TAK $63.3B	313	+3	+1%	$1.24B
21	21 Guardant Health GH $22.2B	296	-3	-1%	$3.21B
22	22 NeoGenomics NEO $2.2B	283	+17	+6%	$1.48B
23	23 Qiagen QGEN $9.55B	278	-5	-2%	$5.4B
24	24 DELISTED Immunogen Inc IMGN	275	+9	+3%	$3.91B
25	25 BioNTech BNTX $22.7B	251	-1	-0.4%	$4.01B